1.
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials
by Böhm, Michael, Prof
The Lancet (British edition), 2017, Vol.389 (10085), p.2226-2237
2.
Renin-angiotensin system and cardiovascular risk
by Schmieder, Roland E, Prof
The Lancet (British edition), 2007, Vol.369 (9568), p.1208-1219
3.
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial
by Esler, Murray D
The Lancet (British edition), 2010, Vol.376 (9756), p.1903-1909
4.
Left Ventricular Hypertrophy and Clinical Outcomes in Hypertensive Patients
by Ruilope, Luis M.
American journal of hypertension, 2008, Vol.21 (5), p.500-508
5.
Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial
by Ott, Christian
Diabetologia, 2016, Vol.59 (12), p.2579-2587
6.
Remodeling of Retinal Small Arteries in Hypertension
by Lehmann, Marina V
American journal of hypertension, 2011, Vol.24 (12), p.1267-1273
7.
Mechanisms for the Clinical Benefits of Angiotensin II Receptor Blockers
by Schmieder, Roland E
American Journal of Hypertension, 2005, Vol.18 (5), p.720-730
8.
Aliskiren, an Orally Effective Renin Inhibitor, Provides Antihypertensive Efficacy Alone and in Combination With Valsartan
by Pool, James L
American journal of hypertension, 2007, Vol.20 (1), p.11-20
9.
Impact of New-Onset Diabetes Mellitus on Development of Atrial Fibrillation and Heart Failure in High-Risk Hypertension (from the VALUE Trial)
by Aksnes, Tonje Amb, MD
The American journal of cardiology, 2008, Vol.101 (5), p.634-638
10.
Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies
by Schmieder, Roland E
Diabetologia, 2014, Vol.57 (10), p.2019-2029
11.
Central arteriovenous anastomosis and hypertension – Authors' reply
by Lobo, Melvin D
The Lancet (British edition), 2015, Vol.386 (10006), p.1821-1822
12.
Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients
by John, Stefan
The American heart journal, 2005, Vol.149 (3), p.473.e1-473.e10
13.
Rationale, Design, and Baseline Characteristics of ARTS-DN: A Randomized Study to Assess the Safety and Efficacy of Finerenone in Patients with Type 2 Diabetes Mellitus and a Clini...
by Ruilope, Luis M
American journal of nephrology, 2015, Vol.40 (6), p.572-581
14.
The Coronary Artery Disease and Renal Failure (CAD-REF) registry: Trial design, methods, and aims
by Brand, Eva, MD, PhD
The American heart journal, 2013, Vol.166 (3), p.449-456.e1
15.
Determinants of cardiovascular risk in haemodialysis patients: post hoc analyses of the AURORA study
by Schneider, Andreas
American journal of nephrology, 2013, Vol.37 (2), p.144-151
16.
Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension
by Ewen, Sebastian
Hypertension (Dallas, Tex. 1979), 2015, Vol.65 (1), p.193-199
17.
23Na Magnetic Resonance Imaging-Determined Tissue Sodium in Healthy Subjects and Hypertensive Patients
by Kopp, Christoph
Hypertension (Dallas, Tex. 1979), 2013, Vol.61 (3), p.635-640
18.
Angiotensin Converting Enzyme Inhibition and Angiotensin II AT1-Receptor Blockade Reduce the Levels of Asymmetrical NG, NG-Dimethylarginine in Human Essential Hypertension
by Delles, Christian
American journal of hypertension, 2002, Vol.15 (7), p.590-593
19.
Angiotensin II-Type 2 Receptor: Emerging Target for Cardiovascular Protection
by Schmieder, Roland E
American journal of hypertension, 2010, Vol.23 (3), p.220-220
20.
First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension
by Böhm, Michael
Hypertension (Dallas, Tex. 1979), 2015, Vol.65 (4), p.766-774
